Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate

Leukemia

Volumn 30, Issue 8, 2016, Pages 1708-1715

  Chaturvedi, A ^a   Araujo Cruz, M M ^a   Jyotsana, N ^a   Sharma, A ^a   Goparaju, R ^a   Schwarzer, A ^a   Gorlich K ^a   Schottmann, R ^a   Struys, E A ^b   Jansen, E E ^b   Rohde, C ^c   Muller Tidow C ^c   Geffers, R ^d   Gohring G ^a   Ganser, A ^a   Thol, F ^a   Heuser, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; 2 OXOGLUTARIC ACID; ALPHA-HYDROXYGLUTARATE; ALPHA-KETOGLUTARIC ACID; GLUTARIC ACID DERIVATIVE; HOMEODOMAIN PROTEIN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; TRANSCRIPTION FACTOR HOXA9;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLONAL EVOLUTION; CONTROLLED STUDY; DNA METHYLATION; ENANTIOMER; FEMALE; GENE EXPRESSION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; LEUKOCYTOSIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL CLONE; GENETICS; ISOMERISM; LEUKEMIA, MYELOID, ACUTE; MUTATION; ONCOGENE; PARACRINE SIGNALING; PATHOLOGY; PHYSIOLOGY; XENOGRAFT;

ANIMALS; CLONE CELLS; GLUTARATES; HETEROGRAFTS; HOMEODOMAIN PROTEINS; HUMANS; ISOCITRATE DEHYDROGENASE; ISOMERISM; KETOGLUTARIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MICE; MUTATION; ONCOGENES; PARACRINE COMMUNICATION;

EID: 84969716651     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.71     Document Type: Article

References (38)

1. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066
2. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773
3. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011; 224: 334-343
4. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17: 72-79
5. Thol F, Damm F, Wagner K, Gohring G, Schlegelberger B, Hoelzer D, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010; 116: 614-616
6. Wagner K, Damm F, Gohring G, Gorlich K, Heuser M, Schafer I, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010; 28: 2356-2364
7. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28: 3636-3643
8. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-Associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-234
9. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2010; 465: 966
10. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG, et al. Cancer-Associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344
11. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009; 324: 261-265
12. Rose NR, McDonough MA, King ON, Kawamura A, Schofield CJ. Inhibition of 2-oxoglutarate dependent oxygenases. Chem Soc Rev 2011; 40: 4364-4397
13. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 2008; 4: 152-156
14. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30
15. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011; 12: 463-469
16. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484-488
17. Heuser M, Araujo Cruz MM, Goparaju R, Chaturvedi A. Enigmas of IDH mutations in hematology/oncology. Exp Hematol 2015; 43: 685-697
18. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012; 488: 656-659
19. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122: 2877-2887
20. Heuser M, Yun H, Berg T, Yung E, Argiropolous B, Kuchenbauer F, et al. Cell of origin in AML: Susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell 2011; 20: 39-52
21. Heuser M, Sly LM, Argiropoulos B, Kuchenbauer F, Lai C, Weng A, et al. Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood 2009; 114: 3983-3993
22. Struys EA, Jansen EE, Verhoeven NM, Jakobs C. Measurement of urinary D-And L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatographytandem mass spectrometry after derivatization with diacetyl-L-Tartaric anhydride. Clin Chem 2004; 50: 1391-1395
23. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80
24. Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics-A bioconductor package for quality assessment of microarray data. Bioinformatics 2009; 25: 415-416
25. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-315
26. Smyth GK. LIMMA: Linear Models for Microarray Data Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Part V. Springer: New York, NY, USA, 2005, pp 397-420
27. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550
28. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, Schlegelberger B, et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006; 108: 3898-3905
29. Heuser M, Yap DB, Leung M, de Algara TR, Tafech A, McKinney S, et al. Loss of MLL5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood 2009; 113: 1432-1443
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2( - delta delta C(T)) method. Methods 2001; 25: 402-408
31. Smith ZD, Gu H, Bock C, Gnirke A, Meissner A. High-Throughput bisulfite sequencing in mammalian genomes. Methods 2009; 48: 226-232
32. Xi Y, Li W. BSMAP: whole genome bisulfite sequence MAPping program. BMC Bioinform 2009; 10: 232
33. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462: 315-322
34. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478
35. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339: 1621-1625
36. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 2015; 21: 178-184
37. Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014; 14: 329-341
38. Kranendijk M, Struys EA, Salomons GS, Van der Knaap MS, Jakobs C. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis 2012; 35: 571-587